Not yet recruiting
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants with First-Line Metastatic Pancreatic Ductal Adenocarcinoma
2025-522563-15-00· Phase 2/3· AbbVie Deutschland GmbH & Co. KG· Source
Recruiting
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
2025-522019-40-00· Phase 1/2· Novartis Pharma AG· Source
Not yet recruiting
Immunotherapy with a JAK1/JAK2 inhibitor (baricitinib) and an mTORC1 inhibitor (sirolimus), alone and in combination, for the control of HIV-1 replication after antiretroviral treatment interruption: a phase II multicenter, multi-arm, multi-stage, randomized, double-blind, placebo-controlled, adaptative trial
NCT07081763· Phase 2· ANRS Maladies Infectieuses Emergentes· Source
Not yet recruiting
Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2
2026-525759-96-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· AstraZeneca· Source
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
2025-523087-20-00· Phase 3· Avidity Biosciences Inc.· Source
Active, not recruiting
Study of an On-Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis
2025-523726-40-00· Phase 3· F. Hoffmann-La Roche AG· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT07227311· Phase 2· GlaxoSmithKline· Source
Recruiting
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
NCT07266831· Phase 2/3· Merck Sharp & Dohme LLC· Source
Recruiting
A study to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo®, in combination with mFOLFOX6 and bevacizumab versus standard of care in participants with non MSI-H/dMMR, PD-L1 positive advanced colorectal cancer.
2024-519590-19-00· Phase 2· Ono Pharmaceutical Co. Ltd.· Source
Recruiting
A Study of LAD191 in Adults With Hidradenitis Suppurativa
NCT07151937· Phase 2· Almirall, S.A.· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225· Phase 3· Incyte Corporation· Source
Recruiting
Interventional, multicenter, open-label, randomized, non-comparative trial evaluating the safety, in terms of HBV virological control, of 2 antiviral treatment relief strategies, in patients co-infected with the HIV-1 and HBV viruses
2023-508634-34-00· Phase 2· Inserm· Source
Active, not recruiting
A study to investigate changes in symptoms in adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with tezepelumab.
2024-513862-20-00· Phase 3· AstraZeneca AB· Source
Recruiting
MICROBIOTA MODIFICATION FOR IMMUNO-ONCOLOGY IN HEPATOCELLULAR CARCINOMA - “MOTHER”
2023-508201-25-00· Phase 2· Centre De Lutte Contre Le Cancer Eugene Marquis· Source
Active, not recruiting
L19IL2/L19TNF in skin cancer patients
NCT05329792· Phase 2· Philogen S.p.A.· Source
Active, not recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· Phase 3· Daiichi Sankyo· Source
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT05963074· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
NCT06385080· Phase 1/2· Janssen Research & Development, LLC· Source
Recruiting
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
NCT06163430· Phase 1/2· Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Source
Recruiting
A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma
2023-503206-37-00· Phase 3· F. Hoffmann-La Roche AG· Source
Active, not recruiting
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT
NCT05983198· Phase 1· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806· Phase 3· Celgene· Source
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240· Phase 3· AbbVie· Source
Recruiting
Aspirin for the Prevention of Preeclampsia and Pregnancy outcomes in nulliparous women after Assisted Reproductive Technology.
2022-500933-10-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source
Active, not recruiting
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
NCT05889182· Phase 3· AbbVie· Source
Active, not recruiting
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05778071· Phase 3· Alexion Pharmaceuticals, Inc.· Source
Recruiting
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05850689· Phase 3· Intra-Cellular Therapies, Inc.· Source
Recruiting
A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors (VAPOR (GETUG T06))
2023-505040-19-00· Phase 2· Institut Gustave Roussy· Source
Recruiting
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904· Phase 3· Iovance Biotherapeutics, Inc.· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT05028348· Phase 3· European Myeloma Network B.V.· Source
Active, not recruiting
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636· Phase 3· AbbVie· Source
Active, not recruiting
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
NCT04994717· Phase 3· Amgen· Source
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236· Phase 3· Pfizer· Source
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04910568· Phase 1· Genentech, Inc.· Source
Active, not recruiting
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
NCT04280718· Phase 2· argenx· Source
Recruiting
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
NCT04325425· Phase 2· Centre Hospitalier Universitaire Dijon· Source
Active, not recruiting
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
NCT04199689· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
NCT03972488· Phase 3· Advanced Accelerator Applications· Source
Active, not recruiting
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105· Phase 2· Regeneron Pharmaceuticals· Source
Active, not recruiting
Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate 76K)
2022-502354-14-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source
Recruiting
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796· Phase 2/3· Celgene· Source
Active, not recruiting
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200· Phase 4· Pharmacyclics Switzerland GmbH· Source
Recruiting
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
NCT02885753· Phase 3· Federation Francophone de Cancerologie Digestive· Source
Active, not recruiting
Neoadjuvant L19IL2/L19TNF- Pivotal Study
NCT02938299· Phase 3· Philogen S.p.A.· Source